Long-term Effects of Raloxifene on Bone Mineral Density, Bone Turnover, and Serum Lipid Levels in Early Postmenopausal Women
Authors:
- Nina H. BjarnasonNBNina H. Bjarnason
- Fredric J. CohenFCFredric J. Cohen
- Aarti ShahASAarti Shah
- Robert LindsayRLRobert Lindsay
- Bruce H. MitlakBMBruce H. Mitlak
- William HusterWHWilliam Huster
- Michael W. DraperMDMichael W. Draper
- Kristine D. HarperKHKristine D. Harper
- Hunter HeathHHHunter Heath
- Carlo GennariCGCarlo Gennari
- Claus ChristiansenCCClaus Christiansen
- 11 December 2000
- journal article
- clinical trial
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 160 (22) , 3444-3450
Abstract
Research from JAMA Internal Medicine — Long-term Effects of Raloxifene on Bone Mineral Density, Bone Turnover, and Serum Lipid Levels in Early Postmenopausal Women — Three-Year Data From 2 Double-blind, Randomized, Placebo-Controlled TrialsKeywords
This publication has 17 references indexed in Scilit:
- Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With RaloxifeneResults From a 3-Year Randomized Clinical TrialJAMA, 1999
- Bone Densitometry: A New, Highly Responsive Region of Interest in the Distal Forearm to Monitor the Effect of Osteoporosis TreatmentOsteoporosis International, 1999
- P-71. Effects of Raloxifene on the Endometrium in Healthy Postmenopausal WomenMenopause, 1998
- Prevention of Bone Loss with Alendronate in Postmenopausal Women under 60 Years of AgeNew England Journal of Medicine, 1998
- Selective Estrogen Receptor Modulators: An Alternative to Hormone Replacement TherapyExperimental Biology and Medicine, 1998
- Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal WomenNew England Journal of Medicine, 1997
- The effect on bone mass and bone markers of different doses of ibandronate: A new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: A 1-year, randomized, double-blind, placebo-controlled dose-finding studyBone, 1996
- Increased bone turnover in late postmenopausal women is a major determinant of osteoporosisJournal of Bone and Mineral Research, 1996
- Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal OsteoporosisNew England Journal of Medicine, 1995
- Measurement of serum osteocalcin with a human-specific two-site immunoradiometric assayJournal of Bone and Mineral Research, 1992